According to a new report Global Benign Prostatic Hyperplasia Therapeutics Market, published by KBV research, The Global Benign Prostatic Hyperplasia Therapeutics Market size is expected to reach $7.4 billion by 2027, rising at a market growth of 4.6% CAGR during the forecast period.
The Mono Drug Therapy market acquired maximum revenue share in the Global Benign Prostatic Hyperplasia Therapeutics Market by Therapy 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $5.5 billion by 2027. The growth of this segment is attributed to the rising usage of this therapy with an individual drug that is efficient enough to treat the disorder. Moreover, due to the utilization of a single drug, mono drug therapy is also a cost-efficient and accessible therapeutics.
The Alpha Blockers market is generating high growth of 3.6 % during the forecast period. The alpha blockers therapeutics is considered as the first-line treatment for prostate enlargement, however, prazosin and phenoxybenzamine are usually excluded from the treatment because these drugs aren’t completely studied and lack enough data to implement their utilization. These drugs relax the muscles in the prostate as well as the bladder neck, making it easier for urine to flow.
The North America market is the fastest growing region in the Global Benign Prostatic Hyperplasia Therapeutics Market by Region 2020, thereby, achieving a market value of $3.0 billion by 2027. The Europe market is expected to witness a CAGR of 3.9% during (2021 - 2027). Additionally, The Asia Pacific market is expected to witness a CAGR of 6.5% during (2021 - 2027).
Full Report: https://www.kbvresearch.com/benign-prostatic-hyperplasia-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of GlaxoSmithKline PLC (GSK), Astellas Pharma, Inc., Eli Lilly and Company, Allergan PLC (AbbVie), Merck Group (Merck Sharp & Dohme Corp.), Boehringer Ingelheim International GmbH, Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Pfizer, Inc., and Abbott Laboratories.
By Therapy
By Therapeutics Class
By Geography
Companies Profiled
Unique Offerings 
